SCHEMBL20238797

SCHEMBL20238797

COc1ccc(CN(c2nccs2)S(=O)(=O)c2cc(Cl)c(N[C@@H](C)c3ccccc3F)cc2C)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 20/20 0.56
SCN5A Q14524 20/20 0.56
SCN8A Q9UQD0 20/20 0.56
SCN1B Q07699 3/20 0.42
NR1I2 O75469 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29669021 1.00 SCN1A (0.56) SCN1ASCN5ASCN8ASCN1BNR1I2
SCHEMBL20238800 1.00 SCN1A (0.56) SCN1ASCN5ASCN8ASCN1BNR1I2
SCHEMBL29669198 0.95 SCN1A (0.55) SCN1ASCN5ASCN8ASCN1BNR1I2
SCHEMBL29669098 0.95 SCN1A (0.55) SCN1ASCN5ASCN8ASCN1BNR1I2
SCHEMBL20237827 0.95 SCN1A (0.55) SCN1ASCN5ASCN8ASCN1BNR1I2
SCHEMBL20237828 0.95 SCN1A (0.55) SCN1ASCN5ASCN8ASCN1BNR1I2
SCHEMBL20252635 0.94 SCN1A (0.57) SCN1ASCN5ASCN8ASCN1BNR1I2
SCHEMBL20256832 0.92 SCN1A (0.46) SCN1ASCN5ASCN8ASCN1BNR1I2
SCHEMBL29669288 0.91 SCN1A (0.55) SCN1ASCN5ASCN8ASCN1BNR1I2
SCHEMBL20238439 0.91 SCN1A (0.55) SCN1ASCN5ASCN8ASCN1BNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110325531-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2022-05-27 CN disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 US disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 US disclosed
EP-3551626-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2019-10-16 EP disclosed
WO-2018106284-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2018-06-14 WO disclosed
US-20180162868-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2018-06-14 US disclosed
US-20180162868-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents KCND2, SCN1A, CACNA1D SCN1A 2/4885SCN5A 42/4885SCN8A 20/4885
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN1A 1/4885SCN5A 10/4885SCN8A 11/4885
US-20180162868-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN1A 1/4885SCN5A 10/4885SCN8A 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.